Brain Cognition
Project summary
In glioma patients the correlation of self-rated cognitive abilities with HRQOL was never compared with that of objective abilities, nor has the concomitant influence of tumor- and treatment-related and demographic variables ever been taken into consideration. Furthermore, studies on the impact of cognitive functioning on differences between HRQOL-ratings by patients and proxies show contradictory results. On these grounds, given the significant risk of cognitive impairment in brain tumor patients, this study aims at clarifying the impact of self-awareness of cognitive deficits and objective cognitive deficits on self-reported HRQOL and to evaluate if such an impact is a by-product of tumor- and treatment-related variables. Perceived and objective deficits are expected to affect HRQOL differently.
Achievements
Three of five papers published
Future plans
To publish the remaining two papers.
For patients
It is common for people having a brain tumour to struggle to concentrate or pay attention as well as not behaving the same as before the tumour. The health-related Quality of Life score measures how physically and mentally someone is feeling during treatment. We want to know if what is happening to them and being aware of it could influence the way patients report their health-related quality of life.
Publications
- Caramanna I, Reijneveld JC, van de Ven PM, van den Bent M, Idbaih A, Wick W, Taphoorn MJB, Dirven L, Bottomley A, Klein M; EORTC Quality of Life Group and EORTC Brain Tumor Group. Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials. Eur J Cancer. 2023 Jun;186:38-51. doi: 10.1016/j.ejca.2023.02.029. Epub 2023 Mar 8. PMID: 37028200
- Caramanna I, de Kort JM, Brandes AA, Taal W, Platten M, Idbaih A, Frenel JS, Wick W, Preetha CJ, Bendszus M, Vollmuth P, Reijneveld JC, Klein M. Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. Neurooncol Pract. 2022 Mar 13;9(4):310-316. doi: 10.1093/nop/npac022. PMID: 35855458; PMCID: PMC9290884.
- Caramanna I, Bottomley A, Drijver AJ, Twisk J, van den Bent M, Idbaih A, Wick W, Pe M, Klein M, Reijneveld JC; EORTC Quality of Life Group and Brain Tumour Group. Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. Eur J Cancer. 2021 Feb;144:162-168. doi: 10.1016/j.ejca.2020.10.040. Epub 2020 Dec 22. PMID: 33348088.
- Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 https://academic.oup.com/nop/advance-article-abstract/doi/10.1093/nop/npac022/6547909